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prophylaxis with fondaparinux is cost-effective was addressed in
this study. METHODS: A decision analytic model was developed
to compare a four-week fondaparinux regimen with a one-week
regimen. Clinical input parameters were derived from clinical
trials and other published sources. Cost data for Swiss univer-
sity hospitals were obtained from the single service tariffs data-
base (Tarmed), the Swiss Drugs Compendium and the diagnosis
related groups database (AP-DRG) and were expressed in 2004
Swiss francs (CHF). The model simulates a cohort of HFS and
THR patients over 30 days and 5 years. Outcomes were mea-
sured in life-years gained (LYG). Future costs and outcomes were
discounted with an annual rate of four percent. RESULTS: In a
hypothetical cohort of 1000 HFS patients, extended prophylaxis
avoids 10 fatal events and 9 VTEs over a time horizon of 30
days. The corresponding ICER is CHF 2801 per LYG. With a
lower baseline risk for VTE in THR patients, extended fonda-
parinux prophylaxis prevents one fatal event in 1000 patients
over a time horizon of 30 days, yielding an ICER of CHF20,294
per LYG. After ﬁve years, extended prophylaxis is cost saving in
both HFS and THR patients. The model results were robust to
variations of major clinical and cost parameters. CONCLU-
SIONS: Extended prophylaxis with fondaparinux in THR and
HFS patients is cost-effective from a Swiss health care perspec-
tive using a time horizon of 30 days. With a longer time horizon
of ﬁve years, extended prophylaxis with fondaparinux is 
cost-saving.
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OBJECTIVE: To determine the cost-effectiveness of fonda-
parinux compared with enoxaparin for extended prophylaxis
against venous thromboembolism in patients undergoing hip
fracture surgery using Dutch estimates of costs. METHODS:
Costs and effects are modeled using a cohort simulation model.
Short term transition probabilities (until day 30) are based from
placebo controlled trials. Long term probabilities are obtained
from the literature. Resource use and costs were obtained from
a Dutch costing study concerning bleedings and symptomatic
events. Outcome measures were rates of symptomatic throm-
boembolic events, deaths avoided and health care costs. Costs
were in 2003 values. “Conﬁdence intervals” (CI) are obtained
by probabilistic sensitivity analysis. RESULTS: Fondaparinux
was estimated to prevent an additional 158 symptomatic venous
thromboembolic events (per 10,000 patients) at 1 year after
major orthopaedic surgery compared with enoxaparin (95%
CI:163–371). The cost savings (per patient) of using fonda-
parinux over enoxaparin are estimated at €103 (€34–€178). The
number of deaths avoided (per 10,000 patients) is estimated at
103 (57–165). The probability that fondaparinux is both more
effective and cost saving is estimated at 0.9996. CONCLUSION:
Extended prophylaxis with fondaparinux after major orthope-
dic surgery can be expected to result in both better outcomes and
cost savings when compared with extended prophylaxis with
enoxaparin.
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OBJECTIVE: To determine the cost effectiveness of extended
prophylaxis with fondaparinux to prevent venous thromboem-
bolism in patients undergoing hip fracture surgery compared to
short term using UK and Dutch estimates of costs. METHODS:
Costs and effects are modeled using a cohort simulation model.
Short term transition probabilities (until day 30) are obtained
from placebo controlled trials. Long term probabilities are
obtained from the literature. UK resource use and costs were
obtained from a published analysis concerning short term 
prophylaxis. Dutch resource use and costs were estimated in a
separate costing study concerning bleedings and symptomatic
events. Outcome measures were rates of symptomatic throm-
boembolic events, deaths avoided and health care costs. Costs
were in 2004 values. “Conﬁdence intervals” (CI) were obtained
by probabilistic sensitivity analysis. RESULTS: At one year
extending prophylaxis with fondaparinux after major
orthopaedic surgery from 7 to 22 days was estimated to prevent
343 symptomatic venous thromboembolic events (per 10,000
patients) (95% CI:283–391). The additional cost (per patient) of
extending the prophylactic period is estimated at £164
(£117–£212) in the UK and at €66 in The Netherlands. The
number of deaths avoided (per 10,000 patients) is estimated at
138 (89–192). Costs per symptomatic VTE avoided are esti-
mated at £4,788 (£3258–£6906) in the UK and at €1915
(€392–€4021) in The Netherlands. Costs per death avoided 
are estimated at £11,932 (£7220–£20,480) and €4773
(€892–€11,629). When assuming the average survival after
surgery at 6 years, costs per life year gained are estimated at
under £3,000 for the UK and at under €900 for The Nether-
lands. CONCLUSION: Our estimates indicate that extending
the prophylaxis with fondaparinux from 7 to 21 days has an
acceptable balance between cost and outcomes both in the UK
and The Netherlands.
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Oral anticoagulation is indicated for a number of conditions,
including prevention of systemic embolism in patients with
mechanical heart valves, valvular heart disease, myocardial
infarction and atrial ﬁbrillation. VKA are frequently prescribed
as long term treatment. Due to the features of treatment, VKA
have the potential to cause dissatisfaction and reduce QoL.
OBJECTIVES: To assess Health- Related Quality of life
(HRQOL) in patients receiving VKA comparing their health
status with matched controls. METHODS. Ninety-two consec-
utive patients receiving VKA (53 male; age range 37–81 years)
were enrolled among those followed by our anticoagulation
clinic. The more frequent indications for VKA treatment were
atrial ﬁbrillation and venous thromboembolism. Each patient
was matched by age and sex with one control from a database
of a population based naturalistic prospective survey. The
EuroQoL, completed during the enrolment visit, was used to
evaluate HRQOL. To evaluate differences in the ﬁve dimensions
